* Cara Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on August 5 (estimated) for the period ending January 1 0001
* The Stamford Connecticut-based company is expected to report a 83.1% decrease in revenue to $1.174 million from $6.93 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cara Therapeutics Inc is for a loss of 27 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cara Therapeutics Inc is $1.01, above its last closing price of $0.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.40 -0.56 Missed -40.7
Dec. 31 2024 -0.41 -0.59 Missed -43.2
Sep. 30 2023 -0.52 -0.52 Met 0
Jan. 1 0001 -0.53 -0.54 -0.49 Beat -7.7
Jan. -0.51 -0.32 -0.49 Missed 6
1 0001
Dec. 31 2022 -0.35 -0.32 -0.56 Missed -75
Sep. 30 2022 -0.43 -0.42 -0.43 Missed
Jan. 1 0001 -0.25 -0.25 -0.08 Beat 68.4
This summary was machine generated August 2 at 11:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments